Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
On the Downside Radar: financing pressure. About 12.0 months of cash at its recent burn rate (Jun 30, 2026 balance sheet), a shelf registration filed Aug 21, 2026, and no offering in the last 90 days. Of biotech stocks in this setup with 6 to 12 months of cash, 35% sold new shares within three months and 67% were lower 60 trading days later (median -12%). How we know
$22.2MCash on Hand
12mo Cash Runway
Follow NVCT by emailGet an email when NVCT reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about NVCT, unsubscribe in one click. Privacy
📣 What NVCT Says Is Next
In October · “In April, the project was selected as a pilot project under the “Pediatric Anti-tumor Drug R&D Encouragement Pilot Scheme (Starlight Program)” for the indication of pediatric BRAF V600-mutated recurrent or progressive glioma by CDE. · In October, expanded NXP200 Phase 1b data in patients with recurrent or progressive BRAF V600-mutated gliomas were presented at the 2026 ESMO Congress.”
Company press release, Nov 4, 2026 · SEC filing
by year-end · NXP900: “We expect to submit a U.S. IND for NXP200 by year-end, and we look forward to providing additional NXP200 Phase 1b data from China, alongside a Phase 1b data update for NXP900, our SRC-Yes1 kinase inhibitor,in the coming months." "We ended the quarter with approximately $140 million in cash, representing the strongest financial position in Nuvectis’ history," Mr. Bentsur concluded.”
Company press release, Nov 4, 2026 · SEC filing
by year-end · “We plan to submit a U.S. IND for NXP100 by year-end.”
Company press release, Nov 4, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 4, 2026 ·
Earnings Reported Q3 2026 results and a corporate update. Ciprocopan (NXP100) was approved in China in July 2026 for PNH patients previously untreated with complement inhibitors, with a U.S. FDA update expected before year-end. Cash of about $140 million extends runway into 2H 2029. Form 8-K · SEC filing · Press release
Nov 4, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Aug 21, 2026 ·
Financing Entered an open market sale agreement with Jefferies LLC allowing sales of common stock up to $200 million under a new shelf registration, with commissions up to 3.0% of gross proceeds. Terminated its prior at-the-market program on July 20, 2026. Form 8-K · SEC filing
Aug 21, 2026 ·
Financing Nuvectis filed a shelf registration for up to $200,000,000 of securities, including a $75,000,000 at-the-market common stock program with Jefferies LLC. Unsold securities of about $34,821,188 from a prior shelf are carried forward. The stock closed at $23.35 on August 20, 2026. Form S-3 · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Dec 2026 · Phase 1 · Recruiting · Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer Registry primary completion date, not a results date
Mar 2027 · Phase 1 · Active Trial · A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers Registry primary completion date, not a results date
Aug 2027 · Phase 1 · Recruiting · Study of NXP900 With Lorlatinib in ALK+ Lung Cancer Registry primary completion date, not a results date
Also used in these trials (approved or third-party drugs, not NVCT's own candidates): Lorlatinib.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
NVCT holds $22.2M in cash and short-term investments (as of Jun 30, 2026) and burns about $5.5M/quarter from operations,
an estimated runway of 12 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:39 · Moderate
Cash runway 35 months
ATM program on file since Aug 2026 +15
Shelf registration (S-3, Aug 2026) +10
Share count +34% in a year +14
Recent financing filings on SEC EDGAR:
Aug 21, 2026 · Shelf registration with ATM program, up to $75M · S-3
Share count 34,388,908 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full NVCT picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for NVCT and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.